Search the GHTC website

Global health R&D delivers for Colorado

US government investment in global health R&D has delivered

$93.8 million
to Colorado research institutions
1,400+ new jobs
for Colorado
Global health R&D at work in Colorado

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether temporarily halting this mechanism would allow generation of antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Patrick McKern